5 questions for MSD India's boss
This article was originally published in Scrip
MSD India managing director K G Ananthakrishnan's understated style and measured response easily mask the company's strong showing across several product segments and focused approach in markets like India, which is itself currently in a state of flux amid evolving regulations and pressure from the West over intellectual property rights (IPR) issues.
You may also be interested in...
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.